The licenses signed on 15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and melt analysis and will allow Enigma to commercialize HybProbe PCR tests for human and veterinary in vitro diagnostics on a worldwide basis. The two licenses with RMS complement Enigma’s existing patent portfolio as well as intellectual property licensed by Celera Diagnostics for real-time PCR thermal cyclers.
Financial terms were not disclosed.
Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.
Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licenses from Applied Biosystems and Celera Diagnostics for commercialization of real-time PCR instruments. Enigma’s R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.
SOURCE Enigma Diagnostics Limited
CONTACT: UK Contact, Enigma Diagnostics, Deborah Cordingley,
+44-1980-590131, deborah.cordingley@enigmadiagnostics.com; or US Contact,
Media, Andrew Mielach, amielach@rlcinc.com, or Investors, Cecelia Heer,
cheer@rlcinc.com, both of Richard Lewis Communications, Inc.,
+1-212-827-0020, for Enigma Diagnostics Limited
Web site: http://www.enigmadiagnostics.com/
